

19 Feb 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi's R&D chief moves on; Roche's ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 February 2023, including: Leqembi bodes well for [Biogen, Inc.](#); [AbbVie Inc.](#) predicts US Humira erosion; [Sanofi](#)'s R&D chief moves on; [Roche Holding AG](#)'s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Eisai's Leqembi Launch Bodes Well For Biogen In A Pivotal Year](#)" - Scrip, 10 Feb, 2023.)

(Also see "[AbbVie Pinpoints US Humira Erosion At 37% In 2023](#)" - Scrip, 9 Feb, 2023.)

(Also see "[J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief](#)" - Scrip, 13 Feb, 2023.)

(Also see "[Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs](#)" - Scrip, 14 Feb, 2023.)

(Also see "[Scrip Asks...What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence](#)" - Scrip, 10 Feb, 2023.)

[Click here to explore this interactive content online](#) 